Summary
Pfizer Inc. reported a decrease in revenues for both the three-month and six-month periods ending June 29, 2014, compared to the prior year. This decline was primarily attributed to the loss of exclusivity for several key products, the expiration of co-promotion agreements (notably for Enbrel), and ongoing generic competition. Despite revenue challenges, the company demonstrated improved operational efficiency and a lower effective tax rate. Income from continuing operations saw a decrease primarily due to the non-recurrence of a significant patent litigation settlement gain in the prior year. However, adjusted income, which excludes certain one-time items and purchase accounting impacts, showed a substantial increase, indicating underlying operational strength. Pfizer continued its share repurchase program and paid dividends, reflecting a commitment to shareholder returns while managing costs through various initiatives.
Financial Highlights
54 data points| Revenue | $12.77B |
| Cost of Revenue | $2.46B |
| Gross Profit | $10.31B |
| SG&A Expenses | $3.52B |
| Operating Income | $5.17B |
| Interest Expense | $343.00M |
| Net Income | $2.91B |
| EPS (Basic) | $0.46 |
| EPS (Diluted) | $0.45 |
| Shares Outstanding (Basic) | 6.37B |
| Shares Outstanding (Diluted) | 6.44B |
Key Highlights
- 1Revenues declined by 2% for the quarter and 5% for the six-month period compared to the prior year, driven by product exclusivity losses and expiring collaborations.
- 2Income from continuing operations decreased by 18% for the quarter and 16% for the six months, largely due to the absence of a large patent litigation settlement in the prior year.
- 3The effective tax rate improved significantly, decreasing from 33.3% to 27.0% for the quarter and from 31.8% to 24.3% for the six-month period.
- 4Adjusted income, a non-GAAP measure excluding specific items, showed a substantial increase, suggesting underlying operational improvement.
- 5Research and Development (R&D) expenses increased by 15% for the quarter and 4% for the six months, reflecting investments in new drug candidates and late-stage clinical programs.
- 6The company continued its share repurchase program, buying back approximately $2.5 billion worth of stock in the first six months of 2014.
- 7Pfizer ended the period with $3.4 billion in cash and cash equivalents and $30.6 billion in short-term investments, maintaining a strong liquidity position.